- Live Stories
- Young Minds
Miniscule bleeding, clotting cases post Covishield jabs; no clotting events post Covaxin shots: Govt panel
Bleeding and clotting cases following COVID vaccination in India are minuscule
The National AEFI (Adverse Event Following Immunization) Committee report on Monday said that bleeding and clotting cases following Covishield jabs in India are "miniscule" while there were no potential thromboembolic events reported following administration of Covaxin vaccine doses.
Releasing its report on the study conducted on the adverse events following COVID-19 immunisation, the Centre said that bleeding and clotting cases following COVID vaccination in India are minuscule and in line with the expected number of diagnoses of these conditions in the country. The report was submitted by the National AEFI (Adverse Event Following Immunization) Committee to the Ministry of Health & Family Welfare.
Following alerts raised in some countries on post-vaccination “embolic and thrombotic events” particularly with the AstraZeneca-Oxford Covid vaccine, the government decided to conduct an urgent in-depth analysis of the adverse events (AE) in India in light of the global concerns.
The National AEFI committee noted that as of 03 April 2021, 75,435,381 vaccine doses had been administered (Covishield – 68,650,819; Covaxin – 6,784,562). Of these, 65,944,106 were first doses and 9,491,275 second dose. Since the COVID-19 vaccination drive was initiated – more than 23,000 adverse events were reported through the CO-WIN platform reported from 684 of the 753 districts of the country. Of these, only 700 cases (@ 9.3 cases /million doses administered) were reported to be serious and severe nature, the ministry of health and family welfare said in its statement.
"The AEFI Committee has completed an in-depth case review of 498 serious and severe events, of which 26 cases have been reported to be potential thromboembolic (formation of a clot in a blood vessel that might also break loose and carried by the blood stream to plug another vessel) events – following the administration of Covishield vaccine – with a reporting rate of 0.61 cases/ million doses," the statement further read.
Covishield continues to have a definite positive benefit risk profile with tremendous potential to prevent infections and reduce deaths due to COVID-19 across the world and in India, the MoHFW said.
Covishield is being manufactured by the Serum Institute of India (SII) in Pune. SII is providing its vaccine dose for Rs 150 to the central government, for state governments it has fixed the price at Rs 300 and Rs 600 for private hospitals.